BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...
It is a fictional representation created for illustrative purposes only. The U.S. Food and Drug Administration has announced ...
The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
(This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3 ...
Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report) yesterday and set a ...
In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback